학술논문
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
Document Type
Article
Author
Jaeger, Hans ; Overton, Edgar T; Richmond, Gary; Rizzardini, Giuliano; Andrade-Villanueva, Jaime Federico; Mngqibisa, Rosie; Hermida, Antonio Ocampo; Thalme, Anders; Belonosova, Elena; Ajana, Faïza; Benn, Paul D; Wang, Yuanyuan; Hudson, Krischan J; Español, Carlos Martín; Ford, Susan L; Crauwels, Herta; Margolis, David A; Talarico, Christine L; Smith, Kimberly Y; van Eygen, Veerle; Van Solingen-Ristea, Rodica; Vanveggel, Simon; Spreen, William R
Source
In The Lancet HIV November 2021 8(11):e679-e689
Subject
Language
ISSN
2352-3018